2DelgadoE, Luque MA, Alcantara Aet al. Glucagon - like peptide - 1 binding to rat skeletal muscle. Peptides 1995 ; 16:225 - 229.
3Green BD, Liu HK, McCluskey JT, et al. Function of a long - term, GLP - 1 - treated,insulin - secreting cell line is improve by prevent DPP - Ⅳ - mediated degradation of GLP - 1. Diabetes Obes Metab 2005;7(5) :563 -569.
4Dennls Ms, Zhang M, Meng YG, et al. Albamin binding as a general strategy for improving the pharmacokinetics of proteins. J Biolchen 2002 ;277 (38) :35035 - 35043.
5HagemannD, Hoist J J, GethmannA, et al. Glacagon - like peprice - 1 ( GLP - 1 ) sappresses ghrelin levels in humans via increased in satin secretion. Manuscript Requlatory peptides 2007 ; 1 - 18.
6Green BD, Irwin N, Duffy Na. et al. Inhibition or dipeptidy 1 peptidase -Ⅳ activity by metformin enhances the antidiabetic effects of glucagon - like peptide - 1, EurJ Pharmacol 2006 ; 547 ( 1 - 3 ) : 192 - 199.
7Farilla L,Hui H,Bertolotto C,et al. Glucagon - like peptide - 1 promotes is let cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002,143( 11 ) :4397 -4408.
8MizanoA, KuwajimaM, Zshidak. et al. Extrapancreatic action of truncated glucagons - like peptide - 1 in Otsuka Long - Euans Tokushimq Fatty rats, an animal model or non -insuin -deendent diabetes mellitus for non - insulin - dependent diabetes mellitus Metabolism 1997:46177:745 -749.
1Vahl TP, Paty BW, Fuller BD, et al.Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab, 2003,88:1772-1779.
2Delgado E, Luque MA, Alcantara A et al. Glucagon-like peptide-1 binding to rat skeletal muscle. Peptides,1995,16:225-229.
3Montrose-Rafizadeh C, Yang H, Wang Y,et al. Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes. J Cell Physiol,1997,172:275-283.
4Lugari K,Deicas A,Ugolotti D, et al.Evidence for early impairment of glucagon-like peptide-1 induced insuline secretion in human T2DM.Hormone and Metab Res,2002,34:150-154.
5Zander M, Madsbad S, Lysgaard Madsen J,et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and [beta]-cell function in type 2 diabetes: a parallel-group study. Lancet, 2002,359:824-830.
6Ehlers MRW, Roderick EH, Schneider RL,et al.Continuous subcutaneous infusion of recombinant GLP-1 for 7 days dose-dependently improved glycemic controls in type 2 diabetes (Abstract). Diabetes,2002,51 (Suppl 2):A579.
7Quddusi S, Vahl TP, Hanson K,et al.Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans. Diabetes Care,2003,26:791-798.
8Hui H, Nourparvar A, Zhao X,et al. Glucagon-Like Peptide-1 Inhibits Apoptosis of Insulin-Secreting Cells via a Cyclic 5′-Adenosine Monophosphate-Dependent Protein Kinase A and a Phosphatidylinositol 3-Kinase-Dependent Pathway.Endocrinology,2003,144:1444-1455.
9Abraham EJ, Leech CA, Lin JC, et al.Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology,2002,143:3152-3161.
10Meneilly GS, McIntosh CH, Pederson RA,et al. Effect of glucagon-like peptide 1 (7-36 amide) on insulin-mediated glucose uptake in patients with type 1 diabetes. Diabetes Care,2003,26:837-842.
